The Investment Column: Galen
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE SHARES in small pharmaceuticals companies are vulnerable to collapse when their supposed wonderdrugs fail in the last stages of trials. But when shares in Ireland-based pharmaceuticals company Galen fell 20 per cent in October it was because of aborted merger talks.
Although Galen's business is dominated by the supply to other pharmaceuticals companies of services for clinical trials, it also has new products ready for next year. Its prospects depend on keeping its edge in trial services and demand for its new products.
Yesterday's results justified the recovery in its shares from 360p to 542.5p. After a 59 per cent hike in clinical trial services turnover to pounds 12.1m, first-half group sales jumped 29 per cent to pounds 31m. Pre-tax profits soared 26 per cent to pounds 9.5m.
Galen's task is to sustain this growth in the services market, but it's not obvious that it has distinctive abilities. The competition is hotting up. Long-term sales growth for the products division, which makes analgesics and antibiotics, is not guaranteed either. Sales grew by 15 per cent in the half year but Galen expects sales to take off as it attacks the pounds 2.5bn global hormone replacement therapy market with an intravaginal ring, an alternative way of delivering hormone replacement therapy to pills and skin patches.
Galen is confident of finding a global distribution partner following the failure of its merger with Ferring, the Dutch pharmaceuticals group. But assessments of the product's potential market vary from very little to millions of pounds annually.
Housebroker ABN Amro is forecasting pre-tax profits of pounds 18.5m for the full-year, with earnings of 11.7p. That puts Galen on a racy forward earnings multiple of 46 times. That looks expensive for a company yet to prove it can sustain its performance and investors should consider taking profits.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments